STAT

Opinion: Using CRISPR for the ‘smaller wins,’ like making chemotherapy less toxic

Big breakthroughs in cancer treatment are great. But don't overlook the value of smaller wins, which can be big ones for patients.

Although the phrase “war on cancer” was first uttered in 1971, the breakthroughs in biomedical research that have emerged during this decade have supercharged the fight. The introduction of CRISPR-Cas9 — the molecular scissors that can edit DNA — makes the idea of powerful new tools to treat and prevent cancer feel tantalizingly close.

Ambitious efforts to prevent or beat cancer are important, but we can’t overlook or undervalue the incremental breakthroughs that could quickly reach patients and improve lives. What if, for example, we used CRISPR to make chemotherapy a bit less terrible for patients suffering with cancer now? That’s

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks